Patents by Inventor H. Umit Kaniskan

H. Umit Kaniskan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240025868
    Abstract: Disclosed are phenothiazine compounds which reduce Abeta toxicity in vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhage in vivo toxicity as indicated by preserved motor and cognitive function, and SARS-CoV-2 replication. Also disclosed are methods of use thereof for the treatment of disease in a subject in need thereof.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 25, 2024
    Inventors: Charles Mobbs, Jian Jin, Christopher Kellner, H. Umit Kaniskan, Tao Cao, Jianping Hu, James Vicari, Bik Tzu Huang, Yonejung Yoon, Rachel Litke
  • Publication number: 20230391765
    Abstract: Disclosed are Eleven-Nineteen Leukemia (ENL) degradation/disruption compounds including a ENL ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of ENL-mediated diseases.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 7, 2023
    Inventors: Jian Jin, H. Umit Kaniskan, Lihuai Qin, Hong Wen, Xiaobing Shi, Longxia Xu, Zhaoyu Xue
  • Publication number: 20230242496
    Abstract: Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
    Type: Application
    Filed: June 15, 2021
    Publication date: August 3, 2023
    Applicant: Icahn School of Medicine At Mount Sinai
    Inventors: Jian JIN, Marta FILIZOLA, Aneel AGGARWAL, Samir PAREKH, Abhijeet KAPOOR, Shashidhar S. JATIANI, H. Umit KANISKAN, Jianping HU, Yudao SHEN, Fanye MENG, Lihuai QIN, Yulin HAN, Xufen YU, Chengwei ZHANG, Prashasti KUMAR, Rinku JAIN, Clement LEE
  • Publication number: 20230022524
    Abstract: Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation/disruption compounds including a HPK1 ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated diseases.
    Type: Application
    Filed: May 5, 2020
    Publication date: January 26, 2023
    Inventors: Jian Jin, Steven Burakoff, H. Umit Kaniskan, Sansana Sawasdikosol, He Chen, Joshua Brody, Nina Bhardwaj